Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02473757 | Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | enrolling by invitation | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 25, 2026 | clinicaltrials |
| NCT03226704 | Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing | enrolling by invitation | — | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03628612 | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells | enrolling by invitation | Phase 2 | 500 | Autolus LimitedINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT07168486 | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | enrolling by invitation | Phase 1 | 15 | University of Maryland, BaltimoreOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07103863 | Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis(AL-CA) | enrolling by invitation | — | 49 | Beijing Anzhen HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06767891 | Real-world Study of Acalabrutinib(RESA) | enrolling by invitation | — | 160 | Ruijin HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07784309 | A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies | enrolling by invitation | Phase 1 | 13 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06472830 | MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study(MAGIC) | enrolling by invitation | — | 1,000 | Mayo ClinicOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06795126 | Little NIRVANA for Pediatric Pain and Anxiety | enrolling by invitation | N/A | 130 | Nationwide Children's HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03689595 | Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) | enrolling by invitation | — | 30,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05669989 | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | enrolling by invitation | Phase 2 | 70 | SanofiINDUSTRY | 17 | Jul 31, 2026 | clinicaltrials |
| NCT05673551 | VR-PAT During Home Burn Dressings - Multisite | enrolling by invitation | N/A | 220 | Nationwide Children's HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT00923442 | Biology Studies of Hematologic Cancers | enrolling by invitation | — | 550 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04996706 | Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study(LEO) | enrolling by invitation | — | 21,000 | Mayo ClinicOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07690761 | Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant(Rituximab+ Zan) | enrolling by invitation | Phase 2 | 12 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07499128 | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event | enrolling by invitation | N/A | 136 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06985576 | Long-term Study to Evaluate Safety and Persistence of GF-CART01 | enrolling by invitation | — | 18 | GenomeFrontier Therapeutics TW Co., Ltd.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06665490 | Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash | enrolling by invitation | — | 15 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07515430 | The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia | enrolling by invitation | — | 138 | Sun Yat-sen UniversityOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06211413 | Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors(SENTINEL) | enrolling by invitation | — | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07474051 | Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials(PERSIST) | enrolling by invitation | — | 178 | AvenCell Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05332054 | Long-Term Follow-up Study(LTFS) | enrolling by invitation | — | 150 | Caribou Biosciences, Inc.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07410403 | AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities(AI) | enrolling by invitation | — | 10 | Fuling ZhouOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07348575 | A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma | enrolling by invitation | Phase 3 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT00186147 | Bone Marrow Grafting for Leukemia and Lymphoma | enrolling by invitation | — | 9,999 | Stanford UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07258680 | BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas(BrEto-TCL) | enrolling by invitation | Phase 3 | 114 | N.N. Petrov National Medical Research Center of OncologyOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07173790 | Watch and Wait or Worry and Wait in Indolent Lymphoma | enrolling by invitation | — | 250 | Seoul National University HospitalOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06544798 | Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia | enrolling by invitation | Phase 2 | 276 | MeiraGTx, LLCINDUSTRY | 2 | Oct 16, 2025 | clinicaltrials |
| NCT02646839 | KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | enrolling by invitation | Phase 2 | 50 | Michael PulsipherOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06931613 | Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment | enrolling by invitation | Phase 2 | 20 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06560879 | Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia | enrolling by invitation | Phase 2 | 120 | National Institute of Pediatrics, MexicoOTHER_GOV | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06871007 | Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma | enrolling by invitation | Phase 1 / Phase 2 | 22 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06848738 | Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound(IMPROVED) | enrolling by invitation | N/A | 362 | Zealand University HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06711679 | Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia | enrolling by invitation | Phase 4 | 180 | Yilin ZhaoOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05509855 | A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 | enrolling by invitation | — | 44 | Allotera TherapeuticsINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT06583395 | Quest to Analyze One Thousand Humans Meditating(QUANTUM) | enrolling by invitation | — | 3,000 | Tobias Moeller-BertramINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05775224 | ASH Research Collaborative Data Hub | enrolling by invitation | — | 100,000 | ASH Research CollaborativeOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT04210791 | Autologous Stem Cell Transplantation for Patients With AL Amyloidosis | enrolling by invitation | — | 500 | Nanjing University School of MedicineOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04491721 | Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL | enrolling by invitation | — | 407 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03815279 | A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)(iStopMM) | enrolling by invitation | Phase 2 | 80 | Landspitali University HospitalOTHER | 1 | Aug 16, 2019 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials